Cardiopulmonary Exercise Testing Prognostic in Aortic Stenosis

This article originally appeared here.
Share this content:
Cardiopulmonary Exercise Testing Prognostic in Aortic Stenosis
Cardiopulmonary Exercise Testing Prognostic in Aortic Stenosis

THURSDAY, Aug. 24, 2017 (HealthDay News) -- For patients judged as symptomatic or questionably symptomatic for aortic stenosis, an initially conservative management strategy results in good prognosis if cardiopulmonary exercise testing (CPET) does not indicate significant hemodynamic compromise, according to a study published in the Sept. 1 issue of The American Journal of Cardiology.

Van D. Le, Ph.D., from Roskilde University Hospital in Denmark, and colleagues examined whether CPET is prognostically useful for patients judged asymptomatic or questionably symptomatic for aortic stenosis with aortic valve area index <0.6 cm²/m² and left ventricular ejection fraction ≥0.50. Participants were managed conservatively if they had normal peak oxygen consumption and peak oxygen pulse (group 1) or subnormal peak oxygen consumption or peak oxygen pulse with CPET data indicating pathologies other than hemodynamic compromise from aortic stenosis (group 2).

One hundred one patients were included (median age, 75 years) and 67 percent were judged as questionably symptomatic. The researchers found that the rates of unexpected cardiac death and unexpected hospitalization with heart failure were 0 and 6.0 percent, respectively, at a follow-up of 24 ± 6 months. All-cause mortality was 4 percent, relative to 8.0 percent in a population matched for age and gender. For groups 1 and 2, 37.1 and 38.7 percent, respectively, succumbed to cardiac death, or were hospitalized for heart failure, or underwent valve replacement.

"In conclusion, if CPET does not indicate a significant hemodynamic compromise because of aortic stenosis, an initially conservative strategy results in a good prognosis and an acceptable event rate," the authors write.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »